top of page

Alcohol industry representatives descended on Washington, D.C. earlier this month to urge members of Congress to create a federal regulatory framework for intoxicating hemp-derived products such as cannabinoid-infused beverages—a market segment that’s ballooned since the legalization of hemp through the 2018 Farm Bill.

Members of the Wine & Spirits Wholesalers of America (WSWA) met with lawmakers and staffers to advocate for three key policy priorities that the group says is based on “sound principles of alcohol distribution.” They include banning synthetic THC, setting up a federal system for testing and labeling products and establishing state-level power to regulate retail sales.

“WSWA members are committed to responsible industry growth and consumer safety,” Ryan Mosses, CEO of alcohol wholesaler Best Brands and a member of WSWA’s board of directors, said in a statement about the action. “Legislative fly-ins like this are invaluable opportunities for our members to engage directly with lawmakers, share industry insights, and advocate for smart, science-backed regulations that benefit both businesses and consumers.”

Michael Bilello, the group’s executive vice president of communications and marketing, said on social media that the message to lawmakers was clear: “Federal regulation of hemp-derived beverages is essential. Cannabis should be regulated—and enjoyed—responsibly by adult consumers.”

WSWA is urging lawmakers to clarify rules around hemp-derived cannabinoid products in the next federal Farm Bill. The group said in a press release that it “believes the next Farm Bill should explicitly allow for the production of only naturally derived THC products from hemp (specifically Delta-9) while explicitly granting individual states primary authority to regulate distribution and retail sales, including state level prohibition, to consumers over the age of 21 within their own borders.”

WSWA members just wrapped a successful fly-in on Capitol Hill. Their message was clear: federal regulation of hemp-derived beverages is essential. Cannabis should be regulated—and enjoyed—responsibly by adult consumers.

Read more: https://t.co/tS5AztmmUu

#Hemp#cannabis#Newspic.twitter.com/XGogG3BEGS

— Michael Bilello (@BilelloPR) April 21, 2025


WSWA similarly called on Congress last yar to create a regulatory framework for hemp-based intoxicating cannabinoids rather than impose an outright ban, as was then being proposed.

“We strongly advocate for clear federal rules and regulations that define intoxicating hemp compounds and to grant states the authority to regulate these products within their borders,” the trade association said at the time.

The alcohol industry in recent years has been increasingly involved in lobbying on marijuana issues. That’s in part due to expanding marijuana markets that are competing with alcohol sales.

This month’s lobbying effort, for instance, came alongside a separate policy memo from another alcohol trade group, the American Beverage Licensees (ABL), which argued that only by businesses licensed to sell alcohol should be able to carry intoxicating hemp products.

“States should restrict the sale of intoxicating THC products to businesses licensed to sell beverage alcohol and that are regularly inspected for compliance with laws aimed at preventing sales to individuals under 21,” the memo says.

The group contends that alcohol retailers, “with many decades of proven compliance, are best positioned to sell these products.”

Regulators should also treat cannabis similar to alcohol, the two-page policy memo says, such as by establishing licensing requirements, clear labeling standards and restrictions on advertising. “It may also include limits on potency per serving,” the alcohol trade group asserted.

A report from Bloomberg Intelligence (BI) last year called cannabis a “significant threat” to the alcohol industry, citing survey data that suggests more people are using cannabis as a substitute for alcoholic beverages such a beer and wine.

The report projected that slumping sales of wine and spirits “may extend indefinitely,” which will “stem largely” from the increased consumer access to “legal cannabis” and other alternative products.

“The use of cannabis among consumers is on the rise, and we believe it’s being substituted for alcoholic beverages,” BI analysts wrote. “We also anticipate that increasing US consumer access to recreational marijuana will be a significant threat to all alcoholic drinks, particularly beer and wine, given their lower price points relative to liquor.”

Last November, meanwhile, a beer industry trade group put out a statement of guiding principles to address what it called “the proliferation of largely unregulated intoxicating hemp and cannabis products,” warning of risks to consumers and communities resulting from THC consumption.

The Beer Institute advised in the document that lawmakers impose a federal excise tax on both hemp and cannabis products, “with the tax rate set higher than the highest rate for any beverage alcohol product.”

It also urged a “zero tolerance approach” to THC and driving—a policy that could prevent casual cannabis consumers from ever being able to legally drive due to how long the drug’s metabolites stay in the body after use—and recommended keeping in place the federal ban on combining intoxicating cannabinoids and alcohol.

“For decades, America’s brewers and beer importers have demonstrated their commitment to fostering a culture of moderation and the responsible consumption of our products, all within a robust regulatory and and taxation system,” president and CEO Brian Crawford said in a statement at the time. “The current patchwork of intoxicating hemp and cannabis laws and regulations do not meet the same standards to which the beer industry willingly adheres.”

Growing evidence suggests that frequent marijuana use is now more common among Americans than regular alcohol use. A recent study found that more Americans consume cannabis every day than drink alcohol on a daily basis. Since 1992 the per capita rate of daily cannabis consumption in the country has increased nearly 15 times over.

A multinational investment bank said in a 2023 report that marijuana has also become a “formidable competitor” to alcohol, projecting that nearly 20 million more people will regularly consume cannabis over the next five years as booze loses a couple million drinkers. Marijuana sales are estimated to reach $37 billion in 2027 in the U.S., it said, as more state markets come online.

A separate study out of Canada, where marijuana is federally legal, found that legalization was “associated with a decline in beer sales,” suggesting a substitution effect.

Data from a Gallup survey published in August of last year also found that Americans consider marijuana to be less harmful than alcohol, cigarettes, vapes and other tobacco products.

As for hemp-derived cannabinoids, a hemp industry expert told congressional lawmakers earlier this week that the market is “begging” for federal regulations around cannabis products.

At the hearing, Rep. James Comer (R-KY) also inquired about the U.S. Food and Drug Administration’s (FDA) inaction around regulations, sarcastically asking if it’d require “a gazillion bureaucrats that work from home” to regulate cannabinoids such as CBD.

In the absence of FDA rules, states from California to Florida have pushed for sweeping changes to their own laws around consumable hemp products. While much of the focus has been on intoxicating products, federally legal CBD businesses have also found themselves increasingly in the crosshairs.

Meanwhile, as lawmakers prepare to once again take up large-scale agriculture legislation this session, congressional researchers in January provided an overview of the policy landscape around hemp—emphasizing the divides around various cannabis-related proposals among legislators, stakeholders and advocates.

Senate Democrats released the long-awaited draft of 2024 Farm Bill last year that contained several proposed changes to federal hemp laws—including provisions to amend how the legal limit of THC is measured and reducing regulatory barriers for farmers who grow the crop for grain or fiber. But certain stakeholders had expressed concern that part of the intent of the legislation was to “eliminate a whole range of products” that are now sold in the market.

For the time being, the hemp industry continues to face unique regulatory hurdles that stakeholders blame for the crop’s value plummeting in the short years since its legalization. Despite the economic conditions, however, a recent report found that the hemp market in 2022 was larger than all state marijuana markets, and it roughly equaled sales for craft beer nationally.

Trucking Industry Says Positive Marijuana Tests And ‘Sometimes Outdated’ Federal Regulations Are Contributing To National Driver Shortage

 
 
 

Even as more states and some congressional lawmakers pursued bans on consumable hemp products, the industry saw significant growth in 2024, according to a newly released survey from the U.S. Department of Agriculture (USDA).

The National Hemp Report, which USDA conducts annually to assess the economic health of the market, showed that hemp farmers cultivated 45,294 acres of the crop last year, up 64 percent from 2023. And the industry’s value jumped about 40 percent, increasing to $445 million.

As has been the case since hemp was federally legalized under the 2018 Farm Bill, farmers primarily grew for flower, which represented 93 percent of production. While flower can be sold raw, it’s largely used for extraction purposes to manufacture consumable cannabinoid products such as CBD.

From 11,827 acres of floral hemp, farmers yielded 20.8 million pounds in 2024, a 159 percent increase from the 8 million that was produced in 2023.

In 2024, the value of #hemp production in the open and under protection for the US totaled $445 million, up 40% from 2023. See more #AgStats in the National Hemp Report ➡️https://t.co/xZyOr0tj5x

— National Agricultural Statistics Service (@usda_nass) April 17, 2025


That puts the market is a precarious position, with so much value concentrated in a sector of the hemp economy that’s increasingly under threat at the state and federal level as lawmakers seek to curb unregulated consumables—particularly intoxicating cannabinoids such as delta-8 THC that have grown in popularity.

Meanwhile, farmers produced 18,855 acres of hemp for fiber last year, a 56 percent increase. But yields from those plants fell by 21 percent, dropping to 3,205 pounds per acre. Coupled with declining prices, the value of hemp fiber hit $11.2 million, down 2 percent from 2023.

Hemp production for grain rose 22 percent to 4,863 acres, with farmers yielding 3.4 million pounds of grain in 2024. The value of hemp grain grew by 13 percent to $2.6 million.

Farmers who cultivated the cannabis crop for seed saw substantial growth last year, the USDA surveyshowed. With 2,160 acres of hemp for seed in 2024, that marked a 61 percent increase from the prior year. And the overall value of the hemp seed market jumped 482 percent to $16.9 million.

USDA launched its first annual survey in 2021, and it updated the questionnaire in 2022 before distributing it to farmers and releasing a report with findings that showed significant declines in the value and production of the crop in 2022. It followed up with another survey last year.

As the fate of the consumable hemp market remains murky amid legislative pushback, a congressional committee held a hearing on the Food and Drug Administration (FDA) earlier this month—with a hemp industry expert explaining how the market is “begging” for federal regulations around cannabis products.

Lawmakers have consistently raised concerns about FDA’s refusal to establish rules allowing for the marketing of federally legal hemp as a food item or dietary supplement.

One potential legislative solution that U.S. Hemp Roundtable’s Jonathan Miller noted to the committee is a bipartisan bill Sen. Ron Wyden (D-OR) filed last year that would create a federal regulatory framework for hemp-derived cannabinoids.

The legislation would empower states to set their own rules for products such as CBD while also empowering FDA to ensure that certain safety standards are met in the marketplace.

In the absence of FDA rules, states from California to Florida have pushed for sweeping changes to their own laws around consumable hemp products. While much of the focus has been on intoxicating products, federally legal CBD businesses have also found themselves increasingly in the crosshairs.

—Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.—

Meanwhile, as lawmakers prepare to once again take up large-scale agriculture legislation this session, congressional researchers in January provided an overview of the policy landscape around hemp—emphasizing the divides around various cannabis-related proposals among legislators, stakeholders and advocates.

Senate Democrats released the long-awaited draft of 2024 Farm Bill last year that contained several proposed changes to federal hemp laws—including provisions to amend how the legal limit of THC is measured and reducing regulatory barriers for farmers who grow the crop for grain or fiber. But certain stakeholders had expressed concern that part of the intent of the legislation was to “eliminate a whole range of products” that are now sold in the market.

Colorado Governor Could Grant Mass Pardons For Psychedelics-Related Convictions Under Newly Filed Bill

Photo courtesy of Kimzy Nanney.

 
 
 

A GOP congresswoman says she expects the Biden administration’s marijuana rescheduling proposal to be finalized “right before the election, because they want the cannabis votes.” And while she hopes former President Donald Trump will back the change, she also said part of the reason Republicans in Congress have declined to embrace marijuana reform is because they’re “afraid of it.”

Rep. Nancy Mace (R-SC), who is sponsoring a bill to federally legalize marijuana called the States Reform Act, spoke about cannabis election politics, rescheduling prospects and more during an interview with The Dales Report on Monday.

Asked about whether she expects Trump will get behind marijuana reform in light of his recent comments indicating support for decriminalization as more states adopt legalization, Mace said she wasn’t sure. But she noted his past comments in favor of medical cannabis and said she “would like to hear support for rescheduling” from her party’s leader, especially considering that there’s a “statistically significant number of Republicans” in favor of those policies.

“There’s a lot of work to be done, and Republicans need to get on board, because the vast majority of Americans are with me, with you guys, on how to move forward in a very responsible manner,” Mace said during the marijuana-focused podcast interview. “I would allow states to decide how they want to regulate cannabis. That should be a thing that states are involved at their level—whether it’s medical, recreational—how they want to implement it. Different states have done it different ways, with some successes and some failures.”

“I think that, in the GOP realm, people are afraid of it,” the congresswoman said. “People are afraid of being primaried, and they they haven’t polled it, because if they polled it, they would see, ‘oh, wow, there’s actually significantly more support for this position than I realized.'”


She added that there are “so many reasons to [back cannabis reform] as a Republican. Not only is it the “right moral thing to do,” but it’s also “a winning electoral issue—it’s like a win-win situation.”

Mace said her colleagues in Congress are largely “clueless” on the nuances of the marijuana policy debate, particularly as it comes to some of the debates that have played out during the rescheduling effort. To an extent, that means it’s partly the responsibility of stakeholders and advocates to bring legislators the data showing how supporting policy reform is a popular political position, she said.

But as far as this year is concerned, Mace only signaled confidence that the Biden administration would complete rulemaking to move marijuana from Schedule I to Schedule III under the Controlled Substance Act (CSA), as the Justice Department formally proposed in March.

Her States Reform Act to federally deschedule cannabis, meanwhile, has “zero” percent chance of advancing in the GOP-controlled House in the next three weeks, Mace said, noting challenges with the calendar and other legislative priorities.

“Right now, a good effort would be, between now and the end of the year, is I want to educate members about States Reform Act and then ask them to cosponsor it—showing that we can have a growing level of support,” she said.

. @RepNancyMace will be joining us at a special time tomorrow to talk about the current landscape of #cannabis and #hemp in Washington D.C.

This is going to be a can't miss stream. See you all there! $MSOS$MSOXhttps://t.co/aPAeO6FEvm

— The Dales Report (@TheDalesReport) August 25, 2024


She also mentioned that, if rescheduling is ultimately enacted, her legislation will likely be amended ahead of its reintroduction next year. She didn’t provide details on how it might be changed, however.

In April, Mace said in a separate interview with The Dales Report that “if Republicans want to keep the House,” they should pass a marijuana banking bill, arguing that “there are votes” to approve it. She also said it’s “mind-boggling” that Virginia’s GOP governor had vetoed a bill to legalize cannabis sales given the issues’s broad bipartisan popularity.

The congresswoman also weighed in on another controversial development from earlier this year: guidance from a GOP policy committee she sits on that specifically urges members to oppose the SAFE Banking Act and the Cannabis Users’ Restoration of Eligibility (CURE) Act she’s sponsoring on marijuana-related security clearance denials.

“I just, I don’t understand. We don’t need it. We need to move forward, not backwards,” she said of the GOP leadership’s opposition to cannabis reform. “We need to go with where the country is.”

California Officials Fund New Project To Preserve And Protect ‘Legacy Cannabis’ Genetics And Culture

 
 
 

Global SEO Keywords

marihuana, cannabis, cáñamo, CBD, aceite de CBD, bálsamo de CBD, marijuana, hemp, weed, CBD oil, CBD balm, canapa, erba, olio di CBD, balsamo CBD, chanvre, herbe, huile de CBD, baume CBD, Marihuana, Cannabis, Hanf, Gras, CBD Öl, CBD Balsam, maconha, cânhamo, erva, óleo de CBD, bálsamo CBD, hennep, wiet, CBD olie, CBD balsem, hampa, gräs, CBD olja, CBD balsam, hamp, græs, gress, CBD olje, hamppu, ruoho, CBD öljy, CBD balsami, konopie, konopie indyjskie, olej CBD, balsam CBD, konopí, CBD olej, CBD balzám, konope, CBD balzam, marihuána, kannabisz, kender, fű, CBD olaj, CBD balzsam, canabis, cânepă, iarbă, ulei CBD, марихуана, канабис, коноп, CBD масло, CBD балсам, μαριχουάνα, κάνναβη, χασίς, λάδι CBD, βάλσαμο CBD, kanabis, konoplja, trava, CBD ulje, CBD olje, kanapės, kanapės indinės, CBD aliejus, CBD balzamas, marihuāna, kaņepes, CBD eļļa, CBD balzams, marihuaana, kanep, CBD õli, CBD palsam, kannabis, qanneb, żejt CBD, balsam CBD, marijúna, hampur, CBD olía, CBD smyrsl

Disclaimer

Jacob Hooy CBD Lip Balm is free from parabens and artificial colorants and contains no toxins or heavy metals, supporting natural body care. Our products are not intended to diagnose, treat, cure, or prevent any disease, medical condition, or symptom. The information provided on this website is for informational purposes only and must not be considered medical advice, nor a substitute for professional diagnosis, treatment, or guidance provided by qualified physicians, healthcare professionals, or pharmaceutical specialists. Nothing on this website should be interpreted as a recommendation, prescription, or therapeutic claim.

Difresh Spain is an online retail store registered under IAE Group 652.3, specializing in the retail trade of perfumery, cosmetic products, and personal hygiene and care items. NIF: Y3526859-F. E-mail: info@cbdvending.eu - WhatsApp: +34662918154 - Factory adress: Calle Albardín 13, Nave B07, 50720, La cartuja baja, Zaragoza, España. All prices include VAT and free shipping across all European Union countries.

© 2026 - www.cbdvending.euPrivacy Policy

bottom of page